Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Ongoing support by Dr
524,525 Pancreatic cancer Researchers first compared the expression of GLP-1R in human pancreatic cancer tissues with adjacent non-tumorous pancreatic tissues, finding generally lower or absent expression of GLP-1R in pancreatic cancer tissues
Clinical trial data reports improved glycemic control despite glucagon activation, making it a practical tool for studying glucagon-mediated energy expenditure independently of hyperglycemic confounds
Behavioral and care management support are important factors
Patients considering these treatments should discuss their individual risk profile with their prescribing clinician, particularly if they have a history of pancreatic disease
The Phase 2 trial (338 adults, 48 weeks) was published in the New England Journal of Medicine
US$ 26.28
US$ 21.23
US$ 29.74
US$ 25.79
US$ 28.39
